Monitor Baker Brothers' selling activity via Form 4 filings and volume spikes ahead of the FDA advisory committee (July 30) and PDUFA (August 2). Heavy pre-catalyst selling would be a bearish signal. The going-concern warning and upcoming cash need increase the likelihood of dilutive capital raise post-FDA outcome, compounding the overhang risk.
Drug in focus
REPL drug pipeline →TUDRIQEV
● Neutral Named in this S-3/A- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved and commercially available in the U.S. since October 2026.
- Next catalyst
- None dated
What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 27 $8.63entry
- T+1 · 4mo ago −38.01%α −38.25% · $5.35
- T+5 · 4mo ago +29.78%α +28.71% · $11.20
- T+20 · 3mo ago +70.45%α +67.15% · $14.71
- T+60 · 28d ago +28.04%α +24.34% · $11.05
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Replimune filed Amendment No. 1 to its S-3 shelf registration, enabling Baker Brothers affiliates to resell up to 25,103,489 shares (≈30% of current outstanding, including pre-funded warrants). The company receives no proceeds and has a going-concern warning with cash runway only through Q1 2027, while the FDA decision on the RP1 BLA is due August 2, 2026 (advisory committee July 30). This registration overhang adds downside risk ahead of the binary catalyst.
Key Facts
- 25,103,489 shares registered for resale by Baker Bros Life Sciences and 667, L.P. (Baker Bros. Advisors LP), including 14,058,153 shares issuable upon exercise of pre-funded warrants with nominal exercise prices.
- The selling stockholders beneficially own 25.94% of the company's shares as of March 31, 2026.
- Company's independent auditors included a going-concern explanatory paragraph in the FY2026 10-K; cash, equivalents and short-term investments will fund operations only into Q1 2027.
- FDA action date for RP1 BLA resubmission (advanced melanoma) is August 2, 2026, with an advisory committee meeting on July 30, 2026.
- Replimune will not receive any proceeds from the resale; all proceeds go to selling stockholders.
Financial Impact
Potential overhang of ≈$263M at $10.46/share (25.1M shares), represents ~30% of current outstanding shares if all sold.
Risk Factors
- Resale of a large block (25.1M shares) could pressure the stock price, and the registration rights agreement allows selling at any time.
- FDA CRL on August 2 would likely trigger restructuring, impairing equity value further.
- Cash runway only into Q1 2027 forces near-term capital raising, likely dilutive, regardless of FDA outcome.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001104659-26-086680 |
| Document: tm2620954d2_ex5-1.htm | 0001104659-26-086680 |
| Document: tm2620954d2_ex23-1.htm | 0001104659-26-086680 |
| Document: 0001104659-26-086680-index-headers.html | 0001104659-26-086680 |
| Document: 0001104659-26-086680-index.html | 0001104659-26-086680 |
| Document: 0001104659-26-086680.txt | 0001104659-26-086680 |
Track record
32 reports on REPL
9 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers